<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01811953</url>
  </required_header>
  <id_info>
    <org_study_id>1276.8</org_study_id>
    <secondary_id>2012-005156-42</secondary_id>
    <nct_id>NCT01811953</nct_id>
  </id_info>
  <brief_title>Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered Together</brief_title>
  <official_title>Bioequivalence of Empagliflozin/Metformin Fixed Dose Combination Tablets Compared to Single Tablets Administered Together in Healthy Male and Female Volunteers Under Fed and Fasted Conditions (an Open-label, Randomised, Single-dose, Crossover Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Bioequivalence of an empagliflozin/metformin (FDC) tablet compared with single tablets of two
      strength of empagliflozin and metformin (Part I) under fasted and under fed conditions and
      bioequivalence of empagliflozin/metformin (FDC) tablet compared with single tablets
      empagliflozin and metformin under fed conditions (Part II).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity, Empagliflozin</measure>
    <time_frame>1 hour (h) before first drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
    <description>AUC0-inf: area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity for Empagliflozin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity, Metformin</measure>
    <time_frame>1 hour (h) before first drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
    <description>AUC0-inf: area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity for Metformin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Measured Concentration of the Analyte in Plasma, Empagliflozin</measure>
    <time_frame>1 hour (h) before first drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
    <description>Cmax: maximum measured concentration of the analyte in plasma for Empagliflozin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Measured Concentration of the Analyte in Plasma, Metformin</measure>
    <time_frame>1 hour (h) before first drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
    <description>Cmax: maximum measured concentration of the analyte in plasma for Metformin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point, Empagliflozin</measure>
    <time_frame>1 hour (h) before first drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
    <description>AUC0-tz: area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point for Empagliflozin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point, Metformin</measure>
    <time_frame>1 hour (h) before first drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
    <description>AUC0-tz: area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point for Metformin</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1 Empagliflozin/Metformin (T)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fixed-dose-combination tablet, oral with 240 ml water under fasted conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Empagliflozin/Metformin (T)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fixed-dose-combination tablet, oral with 240 ml water under fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 Empagliflozin + Metformin (R)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tablets, oral with 240 ml water under fasted conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 Empagliflozin + Metformin (R)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tablets, oral with 240 ml water under fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 Empagliflozin/Metformin (T)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fixed-dose-combination tablet, oral with 240 ml water under fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 Empagliflozin + Metformin (R)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tablets, oral with 240 ml water under fed conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>medium dose oral administration</description>
    <arm_group_label>4 Empagliflozin + Metformin (R)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>oral administration</description>
    <arm_group_label>4 Empagliflozin + Metformin (R)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>low dose of Empagliflozin oral administration</description>
    <arm_group_label>6 Empagliflozin + Metformin (R)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin/Metformin</intervention_name>
    <description>low dose of Empagliflozin</description>
    <arm_group_label>5 Empagliflozin/Metformin (T)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>oral administration</description>
    <arm_group_label>6 Empagliflozin + Metformin (R)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin/Metformin</intervention_name>
    <description>medium dose of Empagliflozin oral administration</description>
    <arm_group_label>2 Empagliflozin/Metformin (T)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>medium dose oral administration</description>
    <arm_group_label>3 Empagliflozin + Metformin (R)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>oral administration</description>
    <arm_group_label>3 Empagliflozin + Metformin (R)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin/Metformin</intervention_name>
    <description>medium dose of Empagliflozin oral administration</description>
    <arm_group_label>1 Empagliflozin/Metformin (T)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        1. Healthy male and female subjects

        Exclusion criteria:

        1. Any relevant deviation from healthy conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1276.8.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Biberach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2013</study_first_submitted>
  <study_first_submitted_qc>March 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2013</study_first_posted>
  <results_first_submitted>June 26, 2015</results_first_submitted>
  <results_first_submitted_qc>June 26, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 27, 2015</results_first_posted>
  <last_update_submitted>June 26, 2015</last_update_submitted>
  <last_update_submitted_qc>June 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Emp/Met Fasted / Emp+Met Fasted / Emp/Met Fed / Emp+Met Fed</title>
          <description>fixed-dose-combination (FDC) tablet under fasted conditions first; then free dose combination tablets under fasted conditions; then FDC tablet under fed conditions; then free dose combination tablets under fed conditions
Empagliflozin (Emp): 12.5 mg; Metformin (Met): 1000 mg (oral with 240 ml water)</description>
        </group>
        <group group_id="P2">
          <title>Emp/Met Fed / Emp+Met Fed / Emp/Met Fasted / Emp+Met Fasted</title>
          <description>fixed-dose-combination (FDC) tablet under fed conditions first; then free dose combination tablets under fed conditions; then FDC tablet under fasted conditions; then free dose combination tablets under fasted conditions
Empagliflozin (Emp): 12.5 mg; Metformin (Met): 1000 mg (oral with 240 ml water)</description>
        </group>
        <group group_id="P3">
          <title>Emp+Met Fasted / Emp/Met Fasted / Emp+Met Fed / Emp/Met Fed</title>
          <description>free dose combination tablets under fasted conditions first; then fixed-dose-combination (FDC) tablet under fasted conditions; then free dose combination tablets under fed conditions; then FDC tablet under fed conditions
Empagliflozin (Emp): 12.5 mg; Metformin (Met): 1000 mg (oral with 240 ml water)</description>
        </group>
        <group group_id="P4">
          <title>Emp+Met Fed / Emp/Met Fed / Emp+Met Fasted / Emp/Met Fasted</title>
          <description>free dose combination tablets under fed conditions first; then FDC tablet under fed conditions; then free dose combination tablets under fasted conditions; then fixed-dose-combination (FDC) tablet under fasted conditions
Empagliflozin (Emp): 12.5 mg; Metformin (Met): 1000 mg (oral with 240 ml water)</description>
        </group>
        <group group_id="P5">
          <title>Low Dose Emp: Emp/Met / Emp+Met</title>
          <description>fixed-dose-combination tablet under fed conditions first; then free dose combination tablets under fed conditions
Empagliflozin (Emp): 5 mg; Metformin (Met): 1000 mg (oral with 240 ml water)</description>
        </group>
        <group group_id="P6">
          <title>Low Dose Emp: Emp+Met / Emp/Met</title>
          <description>free dose combination tablets under fed conditions first; then fixed-dose-combination tablet under fed conditions
Empagliflozin (Emp): 5 mg; Metformin (Met): 1000 mg (oral with 240 ml water)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated Set (TS): includes all subjects who were dispensed study medication and were documented to have taken at least one dose of investigational treatment</population>
      <group_list>
        <group group_id="B1">
          <title>Emp/Met Fasted / Emp+Met Fasted / Emp/Met Fed / Emp+Met Fed</title>
          <description>fixed-dose-combination (FDC) tablet under fasted conditions first; then free dose combination tablets under fasted conditions; then FDC tablet under fed conditions; then free dose combination tablets under fed conditions
Empagliflozin (Emp): 12.5 mg; Metformin (Met): 1000 mg (oral with 240 ml water)</description>
        </group>
        <group group_id="B2">
          <title>Emp/Met Fed / Emp+Met Fed / Emp/Met Fasted / Emp+Met Fasted</title>
          <description>fixed-dose-combination (FDC) tablet under fed conditions first; then free dose combination tablets under fed conditions; then FDC tablet under fasted conditions; then free dose combination tablets under fasted conditions
Empagliflozin (Emp): 12.5 mg; Metformin (Met): 1000 mg (oral with 240 ml water)</description>
        </group>
        <group group_id="B3">
          <title>Emp+Met Fasted / Emp/Met Fasted / Emp+Met Fed / Emp/Met Fed</title>
          <description>free dose combination tablets under fasted conditions first; then fixed-dose-combination (FDC) tablet under fasted conditions; then free dose combination tablets under fed conditions; then FDC tablet under fed conditions
Empagliflozin (Emp): 12.5 mg; Metformin (Met): 1000 mg (oral with 240 ml water)</description>
        </group>
        <group group_id="B4">
          <title>Emp+Met Fed / Emp/Met Fed / Emp+Met Fasted / Emp/Met Fasted</title>
          <description>free dose combination tablets under fed conditions first; then FDC tablet under fed conditions; then free dose combination tablets under fasted conditions; then fixed-dose-combination (FDC) tablet under fasted conditions
Empagliflozin (Emp): 12.5 mg; Metformin (Met): 1000 mg (oral with 240 ml water)</description>
        </group>
        <group group_id="B5">
          <title>Low Dose Emp: Emp/Met / Emp+Met</title>
          <description>fixed-dose-combination tablet under fed conditions first; then free dose combination tablets under fed conditions
Empagliflozin (Emp): 5 mg; Metformin (Met): 1000 mg (oral with 240 ml water)</description>
        </group>
        <group group_id="B6">
          <title>Low Dose Emp: Emp+Met / Emp/Met</title>
          <description>free dose combination tablets under fed conditions first; then fixed-dose-combination tablet under fed conditions
Empagliflozin (Emp): 5 mg; Metformin (Met): 1000 mg (oral with 240 ml water)</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="12"/>
            <count group_id="B6" value="12"/>
            <count group_id="B7" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.5" spread="6.7"/>
                    <measurement group_id="B2" value="26.5" spread="9.7"/>
                    <measurement group_id="B3" value="28.5" spread="9.5"/>
                    <measurement group_id="B4" value="33.2" spread="7.1"/>
                    <measurement group_id="B5" value="32.8" spread="9.8"/>
                    <measurement group_id="B6" value="32.3" spread="9.6"/>
                    <measurement group_id="B7" value="31.5" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity, Empagliflozin</title>
        <description>AUC0-inf: area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity for Empagliflozin</description>
        <time_frame>1 hour (h) before first drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
        <population>Pharmacokinetic set (PKS): included all subjects of the TS who provided at least one observation for at least one primary PK endpoint and who did not have a protocol violation relevant to the evaluation of Pharmacokinetics.</population>
        <group_list>
          <group group_id="O1">
            <title>1 Empagliflozin/Metformin (T)</title>
            <description>fixed-dose-combination tablet, oral with 240 ml water under fasted conditions
Empagliflozin/Metformin: medium dose of Empagliflozin oral administration</description>
          </group>
          <group group_id="O2">
            <title>2 Empagliflozin/Metformin (T)</title>
            <description>fixed-dose-combination tablet, oral with 240 ml water under fed conditions
Empagliflozin/Metformin: medium dose of Empagliflozin oral administration</description>
          </group>
          <group group_id="O3">
            <title>3 Empagliflozin + Metformin (R)</title>
            <description>tablets, oral with 240 ml water under fasted conditions
Empagliflozin: medium dose oral administration
Metformin: oral administration</description>
          </group>
          <group group_id="O4">
            <title>4 Empagliflozin + Metformin (R)</title>
            <description>tablets, oral with 240 ml water under fed conditions
Empagliflozin: medium dose oral administration
Metformin: oral administration</description>
          </group>
          <group group_id="O5">
            <title>5 Empagliflozin/Metformin (T)</title>
            <description>fixed-dose-combination tablet, oral with 240 ml water under fed conditions
Empagliflozin/Metformin: low dose of Empagliflozin</description>
          </group>
          <group group_id="O6">
            <title>6 Empagliflozin + Metformin (R)</title>
            <description>tablets, oral with 240 ml water under fed conditions
Empagliflozin: low dose of Empagliflozin oral administration
Metformin: oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity, Empagliflozin</title>
          <description>AUC0-inf: area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity for Empagliflozin</description>
          <population>Pharmacokinetic set (PKS): included all subjects of the TS who provided at least one observation for at least one primary PK endpoint and who did not have a protocol violation relevant to the evaluation of Pharmacokinetics.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2810" spread="19.3"/>
                    <measurement group_id="O2" value="2580" spread="20.4"/>
                    <measurement group_id="O3" value="2760" spread="20.0"/>
                    <measurement group_id="O4" value="2570" spread="20.7"/>
                    <measurement group_id="O5" value="988" spread="16.2"/>
                    <measurement group_id="O6" value="927" spread="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assessment of bioequivalence was based upon 2-sided 90% confidence intervals (CIs) for the ratio of the geometric means (gMean), test/reference, for the primary endpoints using an acceptance range of 80.00 to 125.00%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>102.55</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.017</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.531</ci_lower_limit>
            <ci_upper_limit>105.653</ci_upper_limit>
            <estimate_desc>The geometric mean ratio was calculated as the geometric mean of '1 Empagliflozin/Metformin (T)' divided by the geometric mean of '3 Empagliflozin + Metformin (R)'.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assessment of bioequivalence was based upon 2-sided 90% confidence intervals (CIs) for the ratio of the geometric means (gMean), test/reference, for the primary endpoints using an acceptance range of 80.00 to 125.00%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>98.88</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.024</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.879</ci_lower_limit>
            <ci_upper_limit>103.059</ci_upper_limit>
            <estimate_desc>The geometric mean ratio was calculated as the geometric mean of '2 Empagliflozin/Metformin (T)' divided by the geometric mean of '4 Empagliflozin + Metformin (R)'.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assessment of bioequivalence was based upon 2-sided 90% confidence intervals (CIs) for the ratio of the geometric means (gMean), test/reference, for the primary endpoints using an acceptance range of 80.00 to 125.00%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>106.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.018</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>102.728</ci_lower_limit>
            <ci_upper_limit>109.386</ci_upper_limit>
            <estimate_desc>The geometric mean ratio was calculated as the geometric mean of '5 Empagliflozin/Metformin (T)' divided by the geometric mean of '6 Empagliflozin + Metformin (R)'.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity, Metformin</title>
        <description>AUC0-inf: area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity for Metformin</description>
        <time_frame>1 hour (h) before first drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
        <population>PKS: included all subjects of the TS who provided at least one observation for at least one primary PK endpoint and who did not have a protocol violation relevant to the evaluation of Pharmacokinetics.</population>
        <group_list>
          <group group_id="O1">
            <title>1 Empagliflozin/Metformin (T)</title>
            <description>fixed-dose-combination tablet, oral with 240 ml water under fasted conditions
Empagliflozin/Metformin: medium dose of Empagliflozin oral administration</description>
          </group>
          <group group_id="O2">
            <title>2 Empagliflozin/Metformin (T)</title>
            <description>fixed-dose-combination tablet, oral with 240 ml water under fed conditions
Empagliflozin/Metformin: medium dose of Empagliflozin oral administration</description>
          </group>
          <group group_id="O3">
            <title>3 Empagliflozin + Metformin (R)</title>
            <description>tablets, oral with 240 ml water under fasted conditions
Empagliflozin: medium dose oral administration
Metformin: oral administration</description>
          </group>
          <group group_id="O4">
            <title>4 Empagliflozin + Metformin (R)</title>
            <description>tablets, oral with 240 ml water under fed conditions
Empagliflozin: medium dose oral administration
Metformin: oral administration</description>
          </group>
          <group group_id="O5">
            <title>5 Empagliflozin/Metformin (T)</title>
            <description>fixed-dose-combination tablet, oral with 240 ml water under fed conditions
Empagliflozin/Metformin: low dose of Empagliflozin</description>
          </group>
          <group group_id="O6">
            <title>6 Empagliflozin + Metformin (R)</title>
            <description>tablets, oral with 240 ml water under fed conditions
Empagliflozin: low dose of Empagliflozin oral administration
Metformin: oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity, Metformin</title>
          <description>AUC0-inf: area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity for Metformin</description>
          <population>PKS: included all subjects of the TS who provided at least one observation for at least one primary PK endpoint and who did not have a protocol violation relevant to the evaluation of Pharmacokinetics.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10400" spread="23.0"/>
                    <measurement group_id="O2" value="9220" spread="26.4"/>
                    <measurement group_id="O3" value="11000" spread="26.8"/>
                    <measurement group_id="O4" value="9140" spread="22.9"/>
                    <measurement group_id="O5" value="9080" spread="32.7"/>
                    <measurement group_id="O6" value="9060" spread="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assessment of bioequivalence was based upon 2-sided 90% confidence intervals (CIs) for the ratio of the geometric means (gMean), test/reference, for the primary endpoints using an acceptance range of 80.00 to 125.00%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>96.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.03</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>91.25</ci_lower_limit>
            <ci_upper_limit>101.26</ci_upper_limit>
            <estimate_desc>The geometric mean ratio was calculated as the geometric mean of '1 Empagliflozin/Metformin (T)' divided by the geometric mean of '3 Empagliflozin + Metformin (R)'.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assessment of bioequivalence was based upon 2-sided 90% confidence intervals (CIs) for the ratio of the geometric means (gMean), test/reference, for the primary endpoints using an acceptance range of 80.00 to 125.00%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>99.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.04</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.56</ci_lower_limit>
            <ci_upper_limit>106.62</ci_upper_limit>
            <estimate_desc>The geometric mean ratio was calculated as the geometric mean of '2 Empagliflozin/Metformin (T)' divided by the geometric mean of '4 Empagliflozin + Metformin (R)'.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assessment of bioequivalence was based upon 2-sided 90% confidence intervals (CIs) for the ratio of the geometric means (gMean), test/reference, for the primary endpoints using an acceptance range of 80.00 to 125.00%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Geometric mean difference</param_type>
            <param_value>100.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.03</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>95.74</ci_lower_limit>
            <ci_upper_limit>106.14</ci_upper_limit>
            <estimate_desc>The geometric mean ratio was calculated as the geometric mean of '5 Empagliflozin/Metformin (T)' divided by the geometric mean of '6 Empagliflozin + Metformin (R)'.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point, Empagliflozin</title>
        <description>AUC0-tz: area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point for Empagliflozin</description>
        <time_frame>1 hour (h) before first drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
        <population>PKS: included all subjects of the TS who provided at least one observation for at least one primary PK endpoint and who did not have a protocol violation relevant to the evaluation of Pharmacokinetics.</population>
        <group_list>
          <group group_id="O1">
            <title>1 Empagliflozin/Metformin (T)</title>
            <description>fixed-dose-combination tablet, oral with 240 ml water under fasted conditions
Empagliflozin/Metformin: medium dose of Empagliflozin oral administration</description>
          </group>
          <group group_id="O2">
            <title>2 Empagliflozin/Metformin (T)</title>
            <description>fixed-dose-combination tablet, oral with 240 ml water under fed conditions
Empagliflozin/Metformin: medium dose of Empagliflozin oral administration</description>
          </group>
          <group group_id="O3">
            <title>3 Empagliflozin + Metformin (R)</title>
            <description>tablets, oral with 240 ml water under fasted conditions
Empagliflozin: medium dose oral administration
Metformin: oral administration</description>
          </group>
          <group group_id="O4">
            <title>4 Empagliflozin + Metformin (R)</title>
            <description>tablets, oral with 240 ml water under fed conditions
Empagliflozin: medium dose oral administration
Metformin: oral administration</description>
          </group>
          <group group_id="O5">
            <title>5 Empagliflozin/Metformin (T)</title>
            <description>fixed-dose-combination tablet, oral with 240 ml water under fed conditions
Empagliflozin/Metformin: low dose of Empagliflozin</description>
          </group>
          <group group_id="O6">
            <title>6 Empagliflozin + Metformin (R)</title>
            <description>tablets, oral with 240 ml water under fed conditions
Empagliflozin: low dose of Empagliflozin oral administration
Metformin: oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point, Empagliflozin</title>
          <description>AUC0-tz: area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point for Empagliflozin</description>
          <population>PKS: included all subjects of the TS who provided at least one observation for at least one primary PK endpoint and who did not have a protocol violation relevant to the evaluation of Pharmacokinetics.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2770" spread="19.2"/>
                    <measurement group_id="O2" value="2530" spread="20.1"/>
                    <measurement group_id="O3" value="2720" spread="20.0"/>
                    <measurement group_id="O4" value="2510" spread="20.2"/>
                    <measurement group_id="O5" value="962" spread="16.3"/>
                    <measurement group_id="O6" value="903" spread="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assessment of bioequivalence was based upon 2-sided 90% confidence intervals (CIs) for the ratio of the geometric means (gMean), test/reference, for the primary endpoints using an acceptance range of 80.00 to 125.00%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>102.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.017</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.315</ci_lower_limit>
            <ci_upper_limit>105.430</ci_upper_limit>
            <estimate_desc>The geometric mean ratio was calculated as the geometric mean of '1 Empagliflozin/Metformin (T)' divided by the geometric mean of '3 Empagliflozin + Metformin (R)'.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assessment of bioequivalence was based upon 2-sided 90% confidence intervals (CIs) for the ratio of the geometric means (gMean), test/reference, for the primary endpoints using an acceptance range of 80.00 to 125.00%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>98.82</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.024</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.784</ci_lower_limit>
            <ci_upper_limit>103.037</ci_upper_limit>
            <estimate_desc>The geometric mean ratio was calculated as the geometric mean of '2 Empagliflozin/Metformin (T)' divided by the geometric mean of '4 Empagliflozin + Metformin (R)'.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assessment of bioequivalence was based upon 2-sided 90% confidence intervals (CIs) for the ratio of the geometric means (gMean), test/reference, for the primary endpoints using an acceptance range of 80.00 to 125.00%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>105.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.018</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>102.730</ci_lower_limit>
            <ci_upper_limit>109.329</ci_upper_limit>
            <estimate_desc>The geometric mean ratio was calculated as the geometric mean of '5 Empagliflozin/Metformin (T)' divided by the geometric mean of '6 Empagliflozin + Metformin (R)'.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Measured Concentration of the Analyte in Plasma, Empagliflozin</title>
        <description>Cmax: maximum measured concentration of the analyte in plasma for Empagliflozin</description>
        <time_frame>1 hour (h) before first drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
        <population>PKS: included all subjects of the TS who provided at least one observation for at least one primary PK endpoint and who did not have a protocol violation relevant to the evaluation of Pharmacokinetics.</population>
        <group_list>
          <group group_id="O1">
            <title>1 Empagliflozin/Metformin (T)</title>
            <description>fixed-dose-combination tablet, oral with 240 ml water under fasted conditions
Empagliflozin/Metformin: medium dose of Empagliflozin oral administration</description>
          </group>
          <group group_id="O2">
            <title>2 Empagliflozin/Metformin (T)</title>
            <description>fixed-dose-combination tablet, oral with 240 ml water under fed conditions
Empagliflozin/Metformin: medium dose of Empagliflozin oral administration</description>
          </group>
          <group group_id="O3">
            <title>3 Empagliflozin + Metformin (R)</title>
            <description>tablets, oral with 240 ml water under fasted conditions
Empagliflozin: medium dose oral administration
Metformin: oral administration</description>
          </group>
          <group group_id="O4">
            <title>4 Empagliflozin + Metformin (R)</title>
            <description>tablets, oral with 240 ml water under fed conditions
Empagliflozin: medium dose oral administration
Metformin: oral administration</description>
          </group>
          <group group_id="O5">
            <title>5 Empagliflozin/Metformin (T)</title>
            <description>fixed-dose-combination tablet, oral with 240 ml water under fed conditions
Empagliflozin/Metformin: low dose of Empagliflozin</description>
          </group>
          <group group_id="O6">
            <title>6 Empagliflozin + Metformin (R)</title>
            <description>tablets, oral with 240 ml water under fed conditions
Empagliflozin: low dose of Empagliflozin oral administration
Metformin: oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Measured Concentration of the Analyte in Plasma, Empagliflozin</title>
          <description>Cmax: maximum measured concentration of the analyte in plasma for Empagliflozin</description>
          <population>PKS: included all subjects of the TS who provided at least one observation for at least one primary PK endpoint and who did not have a protocol violation relevant to the evaluation of Pharmacokinetics.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="379" spread="23.7"/>
                    <measurement group_id="O2" value="276" spread="24.8"/>
                    <measurement group_id="O3" value="375" spread="27.3"/>
                    <measurement group_id="O4" value="258" spread="28.5"/>
                    <measurement group_id="O5" value="108" spread="16.9"/>
                    <measurement group_id="O6" value="103" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assessment of bioequivalence was based upon 2-sided 90% confidence intervals (CIs) for the ratio of the geometric means (gMean), test/reference, for the primary endpoints using an acceptance range of 80.00 to 125.00%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>102.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.035</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.255</ci_lower_limit>
            <ci_upper_limit>108.351</ci_upper_limit>
            <estimate_desc>The geometric mean ratio was calculated as the geometric mean of '1 Empagliflozin/Metformin (T)' divided by the geometric mean of '3 Empagliflozin + Metformin (R)'.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assessment of bioequivalence was based upon 2-sided 90% confidence intervals (CIs) for the ratio of the geometric means (gMean), test/reference, for the primary endpoints using an acceptance range of 80.00 to 125.00%.</non_inferiority_desc>
            <p_value>0.0082</p_value>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>106.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.063</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>95.863</ci_lower_limit>
            <ci_upper_limit>118.353</ci_upper_limit>
            <estimate_desc>The geometric mean ratio was calculated as the geometric mean of '2 Empagliflozin/Metformin (T)' divided by the geometric mean of '4 Empagliflozin + Metformin (R)'.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assessment of bioequivalence was based upon 2-sided 90% confidence intervals (CIs) for the ratio of the geometric means (gMean), test/reference, for the primary endpoints using an acceptance range of 80.00 to 125.00%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>104.352</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.031</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.152</ci_lower_limit>
            <ci_upper_limit>110.224</ci_upper_limit>
            <estimate_desc>The geometric mean ratio was calculated as the geometric mean of '5 Empagliflozin/Metformin (T)' divided by the geometric mean of '6 Empagliflozin + Metformin (R)'.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Measured Concentration of the Analyte in Plasma, Metformin</title>
        <description>Cmax: maximum measured concentration of the analyte in plasma for Metformin</description>
        <time_frame>1 hour (h) before first drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
        <population>PKS: included all subjects of the TS who provided at least one observation for at least one primary PK endpoint and who did not have a protocol violation relevant to the evaluation of Pharmacokinetics.</population>
        <group_list>
          <group group_id="O1">
            <title>1 Empagliflozin/Metformin (T)</title>
            <description>fixed-dose-combination tablet, oral with 240 ml water under fasted conditions
Empagliflozin/Metformin: medium dose of Empagliflozin oral administration</description>
          </group>
          <group group_id="O2">
            <title>2 Empagliflozin/Metformin (T)</title>
            <description>fixed-dose-combination tablet, oral with 240 ml water under fed conditions
Empagliflozin/Metformin: medium dose of Empagliflozin oral administration</description>
          </group>
          <group group_id="O3">
            <title>3 Empagliflozin + Metformin (R)</title>
            <description>tablets, oral with 240 ml water under fasted conditions
Empagliflozin: medium dose oral administration
Metformin: oral administration</description>
          </group>
          <group group_id="O4">
            <title>4 Empagliflozin + Metformin (R)</title>
            <description>tablets, oral with 240 ml water under fed conditions
Empagliflozin: medium dose oral administration
Metformin: oral administration</description>
          </group>
          <group group_id="O5">
            <title>5 Empagliflozin/Metformin (T)</title>
            <description>fixed-dose-combination tablet, oral with 240 ml water under fed conditions
Empagliflozin/Metformin: low dose of Empagliflozin</description>
          </group>
          <group group_id="O6">
            <title>6 Empagliflozin + Metformin (R)</title>
            <description>tablets, oral with 240 ml water under fed conditions
Empagliflozin: low dose of Empagliflozin oral administration
Metformin: oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Measured Concentration of the Analyte in Plasma, Metformin</title>
          <description>Cmax: maximum measured concentration of the analyte in plasma for Metformin</description>
          <population>PKS: included all subjects of the TS who provided at least one observation for at least one primary PK endpoint and who did not have a protocol violation relevant to the evaluation of Pharmacokinetics.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1580" spread="26.9"/>
                    <measurement group_id="O2" value="1160" spread="17.8"/>
                    <measurement group_id="O3" value="1680" spread="25.8"/>
                    <measurement group_id="O4" value="1180" spread="21.2"/>
                    <measurement group_id="O5" value="1180" spread="23.8"/>
                    <measurement group_id="O6" value="1150" spread="24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assessment of bioequivalence was based upon 2-sided 90% confidence intervals (CIs) for the ratio of the geometric means (gMean), test/reference, for the primary endpoints using an acceptance range of 80.00 to 125.00%.</non_inferiority_desc>
            <p_value>0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>94.87</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.038</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>88.931</ci_lower_limit>
            <ci_upper_limit>101.210</ci_upper_limit>
            <estimate_desc>The geometric mean ratio was calculated as the geometric mean of '1 Empagliflozin/Metformin (T)' divided by the geometric mean of '3 Empagliflozin + Metformin (R)'.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assessment of bioequivalence was based upon 2-sided 90% confidence intervals (CIs) for the ratio of the geometric means (gMean), test/reference, for the primary endpoints using an acceptance range of 80.00 to 125.00%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>97.97</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.035</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.339</ci_lower_limit>
            <ci_upper_limit>103.935</ci_upper_limit>
            <estimate_desc>The geometric mean ratio was calculated as the geometric mean of '2 Empagliflozin/Metformin (T)' divided by the geometric mean of '4 Empagliflozin + Metformin (R)'.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assessment of bioequivalence was based upon 2-sided 90% confidence intervals (CIs) for the ratio of the geometric means (gMean), test/reference, for the primary endpoints using an acceptance range of 80.00 to 125.00%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>102.95</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.034</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97.166</ci_lower_limit>
            <ci_upper_limit>109.082</ci_upper_limit>
            <estimate_desc>The geometric mean ratio was calculated as the geometric mean of '5 Empagliflozin/Metformin (T)' divided by the geometric mean of '6 Empagliflozin + Metformin (R)'.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point, Metformin</title>
        <description>AUC0-tz: area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point for Metformin</description>
        <time_frame>1 hour (h) before first drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30 min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
        <population>PKS: included all subjects of the TS who provided at least one observation for at least one primary PK endpoint and who did not have a protocol violation relevant to the evaluation of Pharmacokinetics.</population>
        <group_list>
          <group group_id="O1">
            <title>1 Empagliflozin/Metformin (T)</title>
            <description>fixed-dose-combination tablet, oral with 240 ml water under fasted conditions
Empagliflozin/Metformin: medium dose of Empagliflozin oral administration</description>
          </group>
          <group group_id="O2">
            <title>2 Empagliflozin/Metformin (T)</title>
            <description>fixed-dose-combination tablet, oral with 240 ml water under fed conditions
Empagliflozin/Metformin: medium dose of Empagliflozin oral administration</description>
          </group>
          <group group_id="O3">
            <title>3 Empagliflozin + Metformin (R)</title>
            <description>tablets, oral with 240 ml water under fasted conditions
Empagliflozin: medium dose oral administration
Metformin: oral administration</description>
          </group>
          <group group_id="O4">
            <title>4 Empagliflozin + Metformin (R)</title>
            <description>tablets, oral with 240 ml water under fed conditions
Empagliflozin: medium dose oral administration
Metformin: oral administration</description>
          </group>
          <group group_id="O5">
            <title>5 Empagliflozin/Metformin (T)</title>
            <description>fixed-dose-combination tablet, oral with 240 ml water under fed conditions
Empagliflozin/Metformin: low dose of Empagliflozin</description>
          </group>
          <group group_id="O6">
            <title>6 Empagliflozin + Metformin (R)</title>
            <description>tablets, oral with 240 ml water under fed conditions
Empagliflozin: low dose of Empagliflozin oral administration
Metformin: oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point, Metformin</title>
          <description>AUC0-tz: area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point for Metformin</description>
          <population>PKS: included all subjects of the TS who provided at least one observation for at least one primary PK endpoint and who did not have a protocol violation relevant to the evaluation of Pharmacokinetics.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10100" spread="21.3"/>
                    <measurement group_id="O2" value="8960" spread="24.5"/>
                    <measurement group_id="O3" value="10700" spread="24.1"/>
                    <measurement group_id="O4" value="8930" spread="22.5"/>
                    <measurement group_id="O5" value="8870" spread="30.8"/>
                    <measurement group_id="O6" value="8850" spread="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assessment of bioequivalence was based upon 2-sided 90% confidence intervals (CIs) for the ratio of the geometric means (gMean), test/reference, for the primary endpoints using an acceptance range of 80.00 to 125.00%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>94.89</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.03</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>89.80</ci_lower_limit>
            <ci_upper_limit>100.26</ci_upper_limit>
            <estimate_desc>The geometric mean ratio was calculated as the geometric mean of '1 Empagliflozin/Metformin (T)' divided by the geometric mean of '3 Empagliflozin + Metformin (R)'.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assessment of bioequivalence was based upon 2-sided 90% confidence intervals (CIs) for the ratio of the geometric means (gMean), test/reference, for the primary endpoints using an acceptance range of 80.00 to 125.00%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>99.31</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.04</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.14</ci_lower_limit>
            <ci_upper_limit>107.03</ci_upper_limit>
            <estimate_desc>The geometric mean ratio was calculated as the geometric mean of '2 Empagliflozin/Metformin (T)' divided by the geometric mean of '4 Empagliflozin + Metformin (R)'.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assessment of bioequivalence was based upon 2-sided 90% confidence intervals (CIs) for the ratio of the geometric means (gMean), test/reference, for the primary endpoints using an acceptance range of 80.00 to 125.00%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANOVA</method>
            <param_type>Geometric mean ratio</param_type>
            <param_value>100.74</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.03</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>95.77</ci_lower_limit>
            <ci_upper_limit>105.96</ci_upper_limit>
            <estimate_desc>The geometric mean ratio was calculated as the geometric mean of '5 Empagliflozin/Metformin (T)' divided by the geometric mean of '6 Empagliflozin + Metformin (R)'.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first trial medication intake until next intake or the end-of-trial visit, 10 days</time_frame>
      <desc>Adverse Evens were reported for all patients who received the specific treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>1 Empagliflozin/Metformin (T)</title>
          <description>fixed-dose-combination tablet, oral with 240 ml water under fasted conditions
Empagliflozin/Metformin: medium dose of Empagliflozin oral administration</description>
        </group>
        <group group_id="E2">
          <title>2 Empagliflozin/Metformin (T)</title>
          <description>fixed-dose-combination tablet, oral with 240 ml water under fed conditions
Empagliflozin/Metformin: medium dose of Empagliflozin oral administration</description>
        </group>
        <group group_id="E3">
          <title>3 Empagliflozin + Metformin (R)</title>
          <description>tablets, oral with 240 ml water under fasted conditions
Empagliflozin: medium dose oral administration
Metformin: oral administration</description>
        </group>
        <group group_id="E4">
          <title>4 Empagliflozin + Metformin (R)</title>
          <description>tablets, oral with 240 ml water under fed conditions
Empagliflozin: medium dose oral administration
Metformin: oral administration</description>
        </group>
        <group group_id="E5">
          <title>5 Empagliflozin/Metformin (T)</title>
          <description>fixed-dose-combination tablet, oral with 240 ml water under fed conditions
Empagliflozin/Metformin: low dose of Empagliflozin</description>
        </group>
        <group group_id="E6">
          <title>6 Empagliflozin + Metformin (R)</title>
          <description>tablets, oral with 240 ml water under fed conditions
Empagliflozin: low dose of Empagliflozin oral administration
Metformin: oral administration</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

